statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB - Free Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $50.00 price...

Genmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC Wainwright

Park Place Capital Corp boosted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 12.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the...

Park Place Capital Corp Buys 535 Shares of Genmab A/S (NASDAQ:GMAB)

Venturi Wealth Management LLC decreased its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 2.9% in the 4th quarter, Holdings Channel reports. The fund owned 23,775 shares of the...

Venturi Wealth Management LLC Sells 715 Shares of Genmab A/S (NASDAQ:GMAB)

Genmab (Otc) (GMAB) has released an update. Genmab A/S is set to acquire ProfoundBio for $1.8 billion, aiming to enhance its oncology portfolio wit...

Genmab Expands Oncology Reach with ProfoundBio Buyout

Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. ProfoundBio...

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart...

Company Announcement COPENHAGEN, Denmark; April 2, 2024 Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...

Transactions in Connection with Share Buy-back Program

Schechter Investment Advisors LLC lessened its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 43.7% during the fourth quarter, according to the company in its most recent 13F filing with the...

Genmab A/S (NASDAQ:GMAB) Shares Sold by Schechter Investment Advisors LLC

Truist Financial restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB - Free Report) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $50.00 price...

Genmab A/S (NASDAQ:GMAB) Given "Buy" Rating at Truist Financial

This indicator may be signaling GNMSF's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Genmab A/S (GNMSF, $306.59) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

GMAB GENMAB A/S